Clinical Trial News Archive - January 2022
January 3, 2022
- Bionomics Initiates Phase 2 PREVAIL Study of BNC210 for the Acute Treatment of Social Anxiety Disorder
- Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster for Individuals 12 Years of Age and Older
January 4, 2022
- Positive EMA opinion for the use of Teysuno in metastatic colorectal cancer
- AbbVie Announces U.S. FDA Granted Breakthrough Therapy Designation (BTD) to Telisotuzumab Vedotin (Teliso-V) for Previously Treated Non-Small Cell Lung Cancer
January 5, 2022
- Moderna Announces First Participant Dosed In Phase 1 Study of its mRNA Epstein-Barr Virus (EBV) Vaccine
- Leiden Medical Center and Intravacc to start clinical trial with new intranasal corona vaccine
- Pfizer and BioNTech Sign New Global Collaboration Agreement to Develop First mRNA-based Shingles Vaccine
January 6, 2022
- Valneva Confirms Clinical Trial and Regulatory Submission Timelines for its Inactivated COVID-19 Vaccine Candidate VLA2001
- SK life science Initiates Phase 3 Clinical Trial of Carisbamate for Lennox-Gastaut Syndrome
- COVID-19 Vaccination Associated with a Small, Temporary Increase in Menstrual Cycle Length, Suggests NIH-Funded Study
January 7, 2022
January 10, 2022
January 11, 2022
- Novel Preventive Vaccine for Parkinson's Disease Would Move into Human Trials
- Life Science Alliance journal publishes results of plitidepsin in patients with COVID-19, which includes additional data on its antiviral activity against Delta and Omicron variants
January 12, 2022
January 13, 2022
- Blood Markers of Brain Cell Damage Higher Over Short Term in COVID-19 Patients than in Alzheimer's Patients
- New Vaxzevria Data Further Support its Use as Third Dose Booster
- GSK and Vir Submit Emergency Use Authorization Application to FDA for Intramuscular Administration of Sotrovimab for the Early Treatment of COVID-19
January 14, 2022
January 17, 2022
- Ascletis Announces U.S. IND Approval of ASC22 (Envafolimab), a Subcutaneously Administered PD-L1 Antibody for Functional Cure of Chronic Hepatitis B
- Akseera Pharma Corp - The Company behind CBD for COVID
January 18, 2022
- BlueRock Therapeutics Announces First Patient Dosed in Canada in Phase 1 Trial in Patients with Advanced Parkinson's Disease
- Pfizer Shares In Vitro Efficacy of Paxlovid Novel COVID-19 Oral Treatment Against Omicron Variant
- Levo Therapeutics Receives Complete Response Letter From FDA for Its New Drug Application for LV-101 (Intranasal Carbetocin) for the Treatment of Prader-Willi Syndrome
January 19, 2022
- ImmVira's MVR-T3011 IV completed first 2 cohorts dose-escalation of U.S. Phase I clinical study with favorable safety data
- FDA Accepts for Review Libtayo (cemiplimab-rwlc) in Combination with Chemotherapy for First-line Treatment of Advanced NSCLC
January 20, 2022
January 21, 2022
- Positive Top-Line Results for bimekizumab in Second Phase 3 Psoriatic Arthritis Study
- Alnylam Presents Positive 18-Month Results from HELIOS-A Phase 3 Study of Investigational Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy
January 24, 2022
- Pusan National University Scientists Reveal Links Between Sperm Quality and Cell Phone Use
- Pfizer and BioNTech Publish Data from Two Laboratory Studies on COVID-19 Vaccine-induced Antibodies Ability to Neutralize SARS-CoV-2 Omicron Variant
- Merck Provides U.S. and Japan Regulatory Update for Gefapixant
- Coronavirus (COVID-19) Update: FDA Limits Use of Certain Monoclonal Antibodies to Treat COVID-19 Due to the Omicron Variant
- The Lancet Publishes Studies Showing Genentech’s Faricimab Improved and Maintained Vision in Two Leading Causes of Vision Loss, Extending Time Between Treatments up to Four Months
January 25, 2022
- Pfizer and BioNTech Initiate Study to Evaluate Omicron-Based COVID-19 Vaccine in Adults 18 to 55 Years of Age
- Gilead Announces Partial Clinical Hold for Studies Evaluating Magrolimab in Combination With Azacitidine
January 26, 2022
- Third of Women Receive Clinical Misdiagnosis of Vaginitis
- Mix-and-Match Trial Finds Additional Dose of COVID-19 Vaccine Safe, Immunogenic
- Moderna Announces First Participant Dosed in Phase 2 Study of Omicron-Specific Booster Candidate and Publication of Data on Booster Durability Against Omicron Variant
January 27, 2022
- Lipocine Announces Peer-Reviewed Publication of Phase 3 Study Results for TLANDO
- Hyperimmune Intravenous Immunoglobulin Does Not Improve Outcomes for Adults Hospitalized with COVID-19
- IAVI and Moderna Launch Trial of HIV Vaccine Antigens Delivered Through mRNA Technology
January 28, 2022
- OLUMIANT (baricitinib) Phase 3 lupus program and FDA review for atopic dermatitis
- Merck and Ridgeback’s Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine, Demonstrated Activity Against Omicron Variant in In Vitro Studies
January 31, 2022
- Eagle Pharmaceuticals on Track to Support Submission of New Drug Application in Second Quarter 2022 for Landiolol, a Beta-1 Adrenergic Blocker
- Novavax Submits Request to the U.S. FDA for Emergency Use Authorization of COVID-19 Vaccine
- Pfizer and Ionis Announce Discontinuation of Vupanorsen Clinical Development Program
Clinical trial results archive
- 2023
- January, February, March
- 2022
- January, February, March, April, May, June, July, August, September, October, November, December
- 2021
- January, February, March, April, May, June, July, August, September, October, November, December
- 2020
- January, February, March, April, May, June, July, August, September, October, November, December
- 2019
- January, February, March, April, May, June, July, August, September, October, November, December
- 2018
- January, February, March, April, May, June, July, August, September, October, November, December
- 2017
- May, June, July, August, September, October, November, December
- 2016
- October
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.